MichaelScordoMD

PubMed

• Phase I Trial of MCARH109, a G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D)-Targeted Chimeric Antigen Receptor T-Cell Therapy for Multiple Myeloma: An Up...
  Eric M Jurgens, Ross S Firestone, Jagrutiben Chaudhari, Kinga Hosszu, Sean M Devlin
  Journal of Clinical Oncology. 2025-02-10
• CD4+ T-Cell Lymphoma Harboring a Chimeric Antigen Receptor Integration in.
  Karlo Perica, Nayan Jain, Michael Scordo, Ruchi Patel, Ozgur Can Eren
  The New England Journal of Medicine. 2025-02-06
• Influence of Obesity on the Efficacy and Toxicity of Patients Undergoing Autologous Hematopoietic Cell Transplantation for Lymphoma.
  Andrew Lin, Nicole Pearl, Jessica Flynn, Sean Devlin, Parastoo Dahi
  Clinical Lymphoma, Myeloma & Leukemia. 2025-02-01

Abstracts/Posters

• Easix and Modified-Easix Are Early Predictors of Severe Cytokine Release Syndrome and Neurotoxicity in Patients Treated with Chimeric Antigen Receptor T Cells
  Michael Scordo, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Dynamic Easix Scores Closely Predict Non-Relapse Mortality after Allogeneic Hematopoietic Cell Transplantation
  Michael Scordo, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• MSKCC Early Experience Using Radiotherapy As a Bridging Strategy for Relapsed Diffuse Large B Cell Lymphoma before CD19 CAR T Therapy
  Michael Scordo, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Weekly Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab (wKRd-D) Combination Therapy Provides Unprecedented MRD Negativity Rates in Newly Diagnosed Multiple My...
  Michael Scordo, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Highly Favorable Outcomes with Salvage Radiation Therapy Followed By Autologous Transplant in Relapsed and Refractory DLBCL Patients with Minimal or No Response to Sal...
  Michael Scordo, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Pre-Transplant Fecal Microbial Diversity Independently Predicts Critical Illness after Hematopoietic Cell Transplantation
  Michael Scordo, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Early Experience Using Radiotherapy As a Salvage Treatment for Relapsed or Refractory Non-Hodgkin Lymphomas Following CD19 Chimeric Antigen Receptor Modified T-Cell Th...
  Michael Scordo, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Impact and Safety of Chimeric Antigen Receptor T Cell Therapy in Vulnerable Older Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma
  Michael Scordo, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Hematological Count Recovery in Patients Undergoing Treatment with Chimeric Antigen Receptor T Cells (CAR T)
  Michael Scordo, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Long-Term Sustained Minimal Residual Disease (MRD) Negativity in Multiple Myeloma Patients Treated with Lenalidomide Maintenance Therapy: A Clinical and Correlative Ph...
  Michael Scordo, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Long-Term Sustained Minimal Residual Disease (MRD) Negativity in Multiple Myeloma Patients Treated with Lenalidomide Maintenance Therapy: A Clinical and Correlative Ph...
  Michael Scordo, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Comparing Gradings of Immune Effector Cells Toxicities: Application of Astct Consensus Grading System and Implications for Clinical Management
  Michael Scordo, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Delayed Neutrophil Engraftment in Patients Receiving Daratumumab As Part of Their First Induction Regimen for Multiple Myeloma
  Michael Scordo, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Join now to see all

Lectures

• Career-Development Lunch Sessions: Adult Clinical Malignant Hematology/BMT 
  60th American Society of Hematology Annual Meeting - 12/1/2018
• MRD-Response Driven Phase I/II Study for Newly Diagnosed Multiple Myeloma Patients Using Higher Doses of Twice-Weekly Carfilzomib (45 and 56 mg/m2) in Combination with... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Homebound Autologous Hematopoietic Cell Transplantation for Plasma Cell Disorders in an Urban Setting Is Safe for Patients and Preferred By Patients and Caregivers 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Double-Unit Cord Blood (CB) Transplantation with Haplo-Identical CD34+ Cells (haplo-dCBT) May Speed Neutrophil Recovery Although Successful Bridging Is Contingent on C... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Dysgeusia Is Associated with Higher Melphalan Pharmacokinetic Levels and Results in Poorer Caloric Intake and Worse Symptom Burden after Autologous Stem Cell Transplan... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Join now to see all